-
-
-
-
-
-
-
Wedbush Upgrades Replimune Group (REPL) to Outperform
-
-
-
-
-
-
-
JPMorgan Reiterates Overweight Rating on Replimune Group (REPL)
-
-
-
-
-
-
-
Replimune Announces Biologics License Application Acceptance and Priority Review for RP1 for the Treatment of Advanced Melanoma
-
-
15,439 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

